|
17 Jul 2019 |
Elios Therapeutics Announces Positive Top-Line Data from Phase IIb Study Evaluating TLPLDC, a Personalized Therapeutic Cancer Vaccine, in Patients with High-Risk Melanoma
|
|
17 Jul 2019 |
Inovio Sharpens Focus On HPV-Related Diseases And Fast-to-Market Product Candidates
|
|
15 Jul 2019 |
New Immune Data from Ongoing ADXS-NEO Phase 1 Study Support Clinical Potential for Neoantigen-Directed Immunotherapies
|
|
15 Jul 2019 |
Neon Therapeutics’ Personal Neoantigen Vaccine Study Demonstrates Prolonged Progression-Free Survival in Advanced or Metastatic Melanoma, Non-Small Cell Lung and Bladder Cancers
|
|
12 Jul 2019 |
HOOKIPA Announces FDA Clearance of IND Application for HB-201 Clinical Trial to Treat HPV-Positive Cancers
|
|
11 Jul 2019 |
Transgene Receives MHRA Approval for Lead myvac™ Individualized Immunotherapy, TG4050, to Commence Clinical Development in HPV Negative Head and Neck Cancers in the UK
|
|
09 Jul 2019 |
Vaxart Enters into Research Collaboration with Janssen to Evaluate Oral Universal Influenza Vaccine
|
|
27 Jun 2019 |
Advaxis Announces Increasing Focus on Neoantigen-Directed Immunotherapies and Closing of Its Phase 3 AIM2CERV Study
|
|
27 Jun 2019 |
FDA to review MenQuadfiTM 1, a meningococcal vaccine candidate
|
|
27 Jun 2019 |
Inovio Completes Enrollment of VGX-3100 Phase 3 Trial (REVEAL 1) for the Treatment of HPV-Related Cervical Pre-cancer
|
|
27 Jun 2019 |
Yisheng Biopharma Receives IND Clearance from China NMPA to Initiate Clinical Trial of YS-ON-001 in the Treatment of Advanced Solid Tumors
|
|
27 Jun 2019 |
ILiAD Biotechnologies Announces First Patient Enrolled in BPZE1 Pertussis Vaccine Multicenter Phase 2b Clinical Trial
|
|
21 Jun 2019 |
Continuation of “Atalante 1” Phase 3 Clinical Trial of Tedopi® in NSCLC Patients Post Checkpoint Inhibitor Failure Following IDMC Recommendation
|
|
21 Jun 2019 |
Valneva Announces Mutual Agreement with GSK to End Strategic Alliance Agreement; Regains Control of R&D
|
|
20 Jun 2019 |
Bavarian Nordic Initiates Phase 3 Trial of Freeze-dried MVA-BN® Smallpox Vaccine
|
|
20 Jun 2019 |
Nouscom Demonstrates Preclinical Proof of Concept for Personalized Cancer Neoantigen Vaccine in Combination With Immune Checkpoint Blockade to Eradicate Large Tumors
|
|
17 Jun 2019 |
VBI Vaccines Announces Positive Top-Line Results from PROTECT, a Pivotal Phase 3 Study of Sci-B-Vac
|
|
09 Jun 2019 |
ALK obtains European approval for its tree SLIT-tablet against allergic rhinitis
|
|
06 Jun 2019 |
Bavarian Nordic Reports Positive Result from ongoing Phase 2 Trial Evaluating BN-Brachyury in Chordoma
|
|
06 Jun 2019 |
Vaccitech Universal Flu Vaccine Passes Phase 2b Clinical Development Milestones
|
|
04 Jun 2019 |
VBI Vaccines Reports Data from Part A of the Ongoing Phase 1/2a Study of VBI-1901 in Recurrent Glioblastoma (GBM) Patients at ASCO 2019
|
|
03 Jun 2019 |
Genocea’s GEN-009 Vaccine Demonstrates Best-in-Class Immune Responses to ATLAS™-selected Neoantigens in Cancer Patients
|
|
03 Jun 2019 |
Nouscom - IND for NOUS-209, an 'off-the-shelf' Neoantigen Cancer Vaccine, Cleared by FDA to Commence Clinical Development in MSI Solid Tumors
|
|
02 Jun 2019 |
SOTIO’s DCVAC/LuCa Significantly Improves Survival in Patients with Stage IV Non-small Cell Lung Cancer
|
|
02 Jun 2019 |
Pivotal Phase 3 ARTEMIS Trial Data Demonstrates Consistent Safety and Efficacy of AR101 in Children and Adolescents with Peanut Allergy
|
